Cosmetic And Personal Care Trademark Review: 10 January
Executive Summary
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
You may also be interested in...
HK inno.N Eyes 2025 Korea Opportunity With mAbxience Denosumab Deal
Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.
Stock Watch: Reinforcements Required As Darzalex Carries J&J
Loss of exclusivity and other competitive pressures will continue to offset J&J’s pharmaceutical growth as its former blockbusters accumulate in ex-growth "other" categories. Can the pipeline take up the slack?
European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast
Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.